ASX:OIL

Stock Analysis Report

Executive Summary

Optiscan Imaging Limited engages in the development and commercialization of confocal endomicroscopic imaging technologies for medical, translational, and pre-clinical applications in Australia, North America, Europe, and Asia.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Optiscan Imaging's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OIL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.9%

OIL

-12.2%

AU Medical Equipment

-7.1%

AU Market


1 Year Return

-42.6%

OIL

30.4%

AU Medical Equipment

6.7%

AU Market

Return vs Industry: OIL underperformed the Australian Medical Equipment industry which returned 30.4% over the past year.

Return vs Market: OIL underperformed the Australian Market which returned 6.7% over the past year.


Shareholder returns

OILIndustryMarket
7 Day-12.9%-12.2%-7.1%
30 Day-12.9%-9.3%-5.3%
90 Day-38.6%-4.9%-3.2%
1 Year-42.6%-42.6%32.6%30.4%11.3%6.7%
3 Year-56.5%-56.5%60.9%53.6%28.2%11.2%
5 Year-50.9%-50.9%102.4%86.5%40.9%9.2%

Price Volatility Vs. Market

How volatile is Optiscan Imaging's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Optiscan Imaging undervalued compared to its fair value and its price relative to the market?

4.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OIL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OIL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OIL is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: OIL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OIL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OIL is overvalued based on its PB Ratio (4.5x) compared to the AU Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is Optiscan Imaging forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Optiscan Imaging has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Optiscan Imaging performed over the past 5 years?

-13.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OIL is currently unprofitable.

Growing Profit Margin: OIL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OIL is unprofitable, and losses have increased over the past 5 years at a rate of -13.9% per year.

Accelerating Growth: Unable to compare OIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OIL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: OIL has a negative Return on Equity (-83.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Optiscan Imaging's financial position?


Financial Position Analysis

Short Term Liabilities: OIL's short term assets (A$3.4M) exceed its short term liabilities (A$818.4K).

Long Term Liabilities: OIL's short term assets (A$3.4M) exceed its long term liabilities (A$2.2K).


Debt to Equity History and Analysis

Debt Level: OIL's debt to equity ratio (7.1%) is considered satisfactory.

Reducing Debt: OIL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: OIL has a high level of physical assets or inventory.

Debt Coverage by Assets: OIL's debt is covered by short term assets (assets are 16.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OIL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OIL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.8% each year


Next Steps

Dividend

What is Optiscan Imaging's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.5%markettop25%5.8%industryaverage1.4%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OIL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OIL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OIL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Optiscan Imaging has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Darren Lurie
Executive Chairman1.8yrsAU$517.27k0.36% A$46.6k
Philip Currie
Non-Executive Director2.6yrsAU$176.13k3.82% A$493.0k
Graeme Mutton
Non-Executive Director1.8yrsAU$49.31k2.29% A$296.0k

1.8yrs

Average Tenure

Experienced Board: OIL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Top Shareholders

Company Information

Optiscan Imaging Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Optiscan Imaging Limited
  • Ticker: OIL
  • Exchange: ASX
  • Founded: 1994
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$12.900m
  • Shares outstanding: 477.78m
  • Website: https://www.optiscan.com

Location

  • Optiscan Imaging Limited
  • 16 Miles Street
  • Mulgrave
  • Victoria
  • 3170
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OILASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 1997
OILCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 1997

Biography

Optiscan Imaging Limited engages in the development and commercialization of confocal endomicroscopic imaging technologies for medical, translational, and pre-clinical applications in Australia, North America, Europe, and Asia. It offers ViewnVivo, a miniaturized fluorescence endomicroscope platform that brings imaging flexibility to preclinical research. The company also provides FIVE2 ViewnVivo system that enables virtual biopsies in living tissue. Optiscan Imaging Limited was founded in 1994 and is headquartered in Mulgrave, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 10:36
End of Day Share Price2020/02/28 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.